Life Science Research Network Wales invites academics from Welsh Universities to apply for part-funded PhD studentships in the area of Drug Discovery and Development. Applications are invited across all therapeutic areas and must demonstrate that they meet the following assessment criteria:
- Research Excellence
- An excellent laboratory
- An area of unmet medical and veterinary need
- Possibility of commercialisation
- Potential to leverage further research funding (e.g. RCUK or the EU)
- Collaboration: including within Wales, across academic disciplines and with third parties such as industry, NHS or charities.
- Timeline and Risk
- Students Training
- Match Funding
The Network will provide £40k towards the costs of a studentship with the balance being provided by external partners or the host institution.
Since Jan 2014 the Network has funded a total of 56 studentships across Wales.
Round 4 Studentships
The network recently funded 13 Studentships in the 4th Round. Funded studentships include (PI and project title):
Prof Morgan, Targeting the terminal pathway in complement-driven disease
Dr Davies, Investigating novel small molecule enzyme inhibitors for treating cognitive decline and dementia
Dr Wang, Inhibiting IL-17 production by blocking endogenous RORγt agonists for the treatment of autoimmune diseases
Dr Tsai, Design and in vitro characterisation of a novel multimodular targeting platform for cancer treatment
Dr Tai, Smart Multifunctional Nanocarriers with Biodegradable and Dual Responsive (pH and temperature) Properties from Hyperbranched Polymers for Targeted Cancer Drug Delivery
Dr Johnson, Multiplexed in vitro assay for genetic toxicity screening
Dr Taylor, Targeting zinc signalling to prevent cell division in cancer
Dr Rozanowska, Novel Drug Therapy For Mitochondrial Optic Neuropathy and other Mitochondrial Diseases
Dr McBride, Developing an ovine model of Alzheimer’s disease
Dr Prokopovich, Nanotechnology induced prolonged antimicrobial activity of antibiotic loaded PMMA bone cements
Prof Sewell, Development of artificially enhanced T cells for targeting cancer
Prof Kanamarlapudi, Targeting of interleukin‐13 receptor (IL‐13R)2 expressing pancreatic cancer by a novel hybrid lytic peptide drug
Dr Lloyd-Evans, Developing new small molecule therapies for lysosomal diseases
Round 3 Studentships
In December 2014 the Network launched the 3rd Studentship round. Funded studentships include (PI and project title):
Dr Heard, Towards the repurposing existing of topical antimicrobials by ligand complexation.
Prof Hoffmann, Repositioning histone methyltransferase inhibitors as next generation anthelmintics.
Prof Mur, Exploiting natural products from Hops (Humulus lupulus) to suppress tuberculosis.
Prof Sheldon, Manipulation of squalene synthase to limit bacterial infections.
Dr Howell, Treating Progressive Multiple Sclerosis Using A Novel Neuroprotective And Anti-Inflammatory approach.
Dr Del Sol, Companion diagnostic development guides Antibody-Drug Conjugate formulation: Implications for patient stratification and precision medicine.
Dr Cai, Combining carbon monoxide (CO)-releasing molecules with anti-VEGF therapy for triple-negative breast cancer therapy.
Prof Doak, Design and evaluation of an antibody-drug conjugate for prostate cancer treatment.
Prof Brophy, Towards validation of an immune suppressor protein from liver fluke as a drug target.
Prof Triantafilou, Peptides derived from Yersinia pestis V antigen as novel therapeutic interventions for sepsis.
Prof Doak, Mechanistic evaluation of the impact of superparamagnetic iron oxide nanoparticles conjugated with drugs (SPIONd) on intracellular signalling/homeostatic mechanisms.
Dr Creevey, Computational approaches to mining the rumen micro biome for novel antimicrobials.
Dr Gwenin, Testing a novel chemotherapy delivery system using two dinitrobenzamide mustard prodrugs.
Round 2 Studentships
In March 2014 the Network launched the 2nd Studentship round. Funded studentships include (PI and project title):
Prof Hoffmann, Increasing the selectivity and potency of a novel anthelmintic chemical entity.
Dr Westwell, Radiosynthesis of 18 F-labelled pro-nucleotides (ProTides) for Positron Emission Tomography (PET) imaging.
Dr Moseley, Pharmaceutical evaluation of novel tiglianes as modulators of dermal fibroblast-myofibroblast differentiation, scar formation and fibrosis; and elucidation of their underlying mechanisms of action.
Prof Mahenthiralingam, Development of vietnamycin: a novel Burkholderia antibiotic targeting mupirocin resistant methicillin resistant Staphylococcus aureus (MRSA).
Prof Mur, Identifying new antimicrobial drugs in microbes from extreme environments.
Prof Mur, Targeting natural products to counter the challenge of MRSA.
Dr A Jones, Biological evaluation of [L] ddBCNAs as novel cell-targeting antivirals.
Prof Allemann, An Innovative Approach to New Antimicrobial Drugs.
Dr Young, Structure-based design of human P2X4-selective small-molecule modulators.
Dr Pertusati, Diastereoselective Synthesis of Phosphoroamidate Prodrugs.